Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
Although inhibitors targeting elements of the PI3K/AKT/mTOR pathway are promising approaches ... other targeted agents that suppress survival signaling (for example MEK inhibitors, BCL2 family ...
We have shown that inhibitors of PI3K, AKT, and mTOR all relieve feedback, but the details of their effects differ, which suggests why these drugs vary in their in efficacy and toxicity. This work has ...
The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...
The mechanistic (or mammalian) target of rapamycin (mTOR) signaling pathway ... like effects were primarily mediated by Akt signaling in the mPFC, while the anxiolytic effects were associated ...
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...
Ignite Proteomics announces the publication of a significant study in the British Journal of Cancer titled “Functional activation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback